Microbot Medical Inc. confirms no business disruption in the USA or Israel due to current geopolitical events. Employee safety and security remain a top priority, with all personnel operating as usual and internal operations fully functional. The company's commercial focus is on the U.S. market, managed by its dedicated U.S.-based commercial team. Sufficient inventory is maintained in the U.S. to support current customers, with additional stock being built through a U.S.-based third-party logistics partner. Commercial infrastructure is being strengthened, including hiring additional sales representatives and a Director of Health Economics and Outcomes Research (HEOR). The LIBERTY Endovascular Robotic System, FDA cleared, is the only single-use, remotely operated robotic system for peripheral endovascular procedures. The limited market release of LIBERTY commenced in late 2025, with a full market release planned for the Society of Interventional Radiology (SIR) annual meeting in April 2026.